Mustang Bio, Inc. (MBIO)

Market Cap	2.93M -75.4%
Revenue (ttm)	n/a
Net Income	-3.03M
EPS	-0.46
Shares Out	7.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,561
Open	0.3701
Previous Close	0.3701
Day's Range	0.3701 - 0.3923
52-Week Range	0.3701 - 1.6900
Beta	2.09
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: Nasdaq
• Ticker Symbol: MBIO
• Website: https://www.mustangbio.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error